EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION
NCT ID: NCT02917486
Last Updated: 2016-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2016-01-31
2019-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The exhibition is evaluated by population pharmacokinetic modeling.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ECMO piperacillin
patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
blood sample
without ECMO piperacillin
patients in intensive care without ECMO with antiinfective therapy : piperacillin
blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalisation in intensive care
* Treatment with ECMO or without ECMO
* Introducing sepsis treated with an anti-infective molecule studied (piperacillin) for less than 48 hours
* With an arterial catheter
* Patient Information or their next of kin according to the patients status.
Exclusion Criteria
* Major person under legal protection (backup justice, trusteeship, quardianship), person deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Fillatre
Role: PRINCIPAL_INVESTIGATOR
CHU Rennes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pierre Fillatre
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC15_8901
Identifier Type: -
Identifier Source: org_study_id